Author:
Nishio M,Horai T,Horiike A,Nokihara H,Yamamoto N,Takahashi T,Murakami H,Yamamoto N,Koizumi F,Nishio K,Yusa W,Koyama N,Tamura T
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Baillie R, Carlile J, Pendleton N, Schor AM (2001) Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 54: 116–120.
2. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592–603.
3. Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106: 1598–1604.
4. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS
http://ctep.cancer.gov
(2006)
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
. Accessed (2012).
5. Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y (2003) Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604–613.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献